Key result
INSPIRIS RESILIA pulmonary valve replacement yields safe perioperative outcomes but ~54% 2-year valve durability.
Why the study?
The INSPIRIS RESILIA valve, initially designed for the aortic position, was introduced for pulmonary valve replacement in congenital heart disease due to the limited durability of conventional bioprostheses, but evidence on its performance in the pulmonary position was limited and heterogeneous.
What is the effectiveness, hemodynamic performance, and durability of the INSPIRIS RESILIA bioprosthesis in patients with congenital heart disease undergoing pulmonary valve replacement?
Systematic Review (n=204)
Yes
What is the effectiveness, hemodynamic performance, and durability of the INSPIRIS RESILIA bioprosthesis in patients with congenital heart disease undergoing pulmonary valve replacement?
Answers are grounded in this paper and cite their sources.
While the INSPIRIS RESILIA bioprosthesis demonstrates acceptable perioperative safety in the pulmonary position, emerging mid-term data suggest accelerated pulmonary regurgitation and reduced durability when implanted directly into the native right ventricular outflow tract compared with standard bioprostheses or valved conduits.
INTRODUCTION: Pulmonary valve replacement is increasingly common in patients with congenital heart disease. The limited durability of conventional bioprostheses has led to the introduction of the INSPIRIS RESILIA valve, initially designed for the aortic position. However, evidence on its performance in the pulmonary position is limited and heterogeneous. METHODS: A systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement in PubMed®, Excerpta Medica dataBASE, Cochrane Library, and ClinicalTrials. Observational studies with patients undergoing pulmonary valve replacement with the INSPIRIS RESILIA bioprosthesis were included. Data on baseline characteristics, transvalvular gradients, mortality, complications, prosthetic insuficiency, and need for reintervention were extracted. This study was registered in the International Prospective Register of Systematic Reviews (CRD420251117859). RESULTS: Three retrospective cohort studies and two retrospective case series were identified that included pediatric and adult populations, mainly with a diagnosis of tetralogy of Fallot. The findings were consistent in showing adequate perioperative safety. Smaller studies showed favorable results. In contrast, larger studies with longer follow-up reported more rapid progression to moderate/severe pulmonary insuficiency and shorter durability of the bioprosthesis. CONCLUSION: INSPIRIS RESILIA may be associated with acceptable short-term outcomes in pulmonary valve replacement, but its medium- and long-term durability may be inferior to that of reference bioprostheses. Medium- and long-term safety remains inconclusive due to limited follow-up, modest sample sizes, heterogeneity in definitions, possible confounding by anatomical substrate, and study limitations.
No takes yet. Share an insight, caveat, or question.
Pérez et al. (2026) conducted a systematic review in Congenital heart disease (predominantly tetralogy of Fallot) requiring pulmonary valve replacement (n=204). INSPIRIS RESILIA bioprosthetic valve in the pulmonary position vs. Reference bioprostheses or conduits (e.g., PERIMOUNT, Contegra, homografts, Mosaic, Autus) in comparative cohorts was evaluated on Prosthetic valve failure, moderate/severe pulmonary insufficiency, mortality, and need for reintervention (narrative synthesis). INSPIRIS RESILIA pulmonary valve replacement showed acceptable perioperative safety across 204 patients, though freedom from valve failure declined to 53.5% at 24 months in the largest cohort.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: